| Literature DB >> 28889247 |
Cristina Basso1, Beatriz Aguilera2, Jytte Banner3, Stephan Cohle4, Giulia d'Amati5, Rosa Henriques de Gouveia6, Cira di Gioia5, Aurelie Fabre7, Patrick J Gallagher8, Ornella Leone9, Joaquin Lucena10, Lubov Mitrofanova11, Pilar Molina12, Sarah Parsons13, Stefania Rizzo14, Mary N Sheppard15, Maria Paz Suárez Mier2, S Kim Suvarna16, Gaetano Thiene14, Allard van der Wal17, Aryan Vink18, Katarzyna Michaud19.
Abstract
Although sudden cardiac death (SCD) is one of the most important modes of death in Western countries, pathologists and public health physicians have not given this problem the attention it deserves. New methods of preventing potentially fatal arrhythmias have been developed and the accurate diagnosis of the causes of SCD is now of particular importance. Pathologists are responsible for determining the precise cause and mechanism of sudden death but there is still considerable variation in the way in which they approach this increasingly complex task. The Association for European Cardiovascular Pathology has developed these guidelines, which represent the minimum standard that is required in the routine autopsy practice for the adequate investigation of SCD. The present version is an update of our original article, published 10 years ago. This is necessary because of our increased understanding of the genetics of cardiovascular diseases, the availability of new diagnostic methods, and the experience we have gained from the routine use of the original guidelines. The updated guidelines include a detailed protocol for the examination of the heart and recommendations for the selection of histological blocks and appropriate material for toxicology, microbiology, biochemistry, and molecular investigation. Our recommendations apply to university medical centers, regionals hospitals, and all healthcare professionals practicing pathology and forensic medicine. We believe that their adoption throughout Europe will improve the standards of autopsy practice, allow meaningful comparisons between different communities and regions, and permit the identification of emerging patterns of diseases causing SCD. Finally, we recommend the development of regional multidisciplinary networks of cardiologists, geneticists, and pathologists. Their role will be to facilitate the identification of index cases with a genetic basis, to screen appropriate family members, and ensure that appropriate preventive strategies are implemented.Entities:
Keywords: Autopsy; Guidelines; Protocol; Sudden cardiac death
Mesh:
Year: 2017 PMID: 28889247 PMCID: PMC5711979 DOI: 10.1007/s00428-017-2221-0
Source DB: PubMed Journal: Virchows Arch ISSN: 0945-6317 Impact factor: 4.064
Fig. 1After a transection of the aorta 3 cm above the aortic valve, inspection of the coronary ostia location in the proper sinus (LCA=left coronary artery; RCA= right coronary artery)
Fig. 2a Schematic representation of serial cross sectioning of the sub-epicardial coronary artery tree. b A careful inspection of the serial sections is needed not to miss any coronary lesion. A transverse cut of the first tract of the left anterior descending coronary artery appears occluded by thrombosis.
Fig. 3Short axis cross sectioning of the heart specimen from mid-ventricular to apical levels. a gross view of the specimen before cross sectioning. b transverse sections of the heart at the three different levels as represented in a
Fig. 4a Sampling of the myocardium with several transmural blocks, circumferentially along the left ventricle, septum and right ventricle. b An additional sampling of the right ventricular outflow tract myocardium can be also taken
Sampling for further laboratory tests in SD
| Sample | Quantity | Technical aspects and storage | Analyses |
|---|---|---|---|
| Peripheral venous blood | 10–20 ml | Potassium oxalate and sodium fluoride as preservatives, stored at 4° when analyzed promptly after autopsy, otherwise frozen at − 20° | Toxicology |
| Peripheral venous blooda | 10 ml | EDTA, frozen optimally at − 80 °C | Genetic analyses, Virology |
| Serum | 5–10 ml | From peripheral venous blood centrifuged directly after sampling, stored at 4° when analyzed promptly after autopsy, otherwise frozen at − 20° | Toxicology, Chemistry |
| Vitreous humor | 5–10 ml | Stored at 4° when analyzed promptly after autopsy, otherwise frozen at − 20° | Toxicology, Chemistry |
| Hair | Strands (apx 0.2 g) | From the vertex posterior, cut closely to the scalp, pulled out and containing hair bulbs if possible, stored in an aluminum foil, an envelope or in a plastic tube at ambient temperature | Toxicology |
| Urine | 10–20 ml | Stored at 4° when analyzed promptly after autopsy, otherwise frozen at − 20° | Toxicology, Chemistry |
| Bile | All | Stored at 4° when analyzed promptly after autopsy, otherwise frozen at − 20° | Toxicology |
| Pericardial/Cerebrospinal fluids | 5–10 ml | Stored at 4° when analyzed promptly after autopsy, otherwise frozen at − 20° | Toxicology, Chemistry |
| Gastric contents | Whole | Stored at 4° when analyzed promptly after autopsy, otherwise frozen at − 20° | Toxicology |
| Other tissue samplesb | 25–50 g | Stored at 4° when analyzed promptly after autopsy, otherwise frozen at − 20° | Toxicology |
| Heart/spleen | 5 g | Optimally frozen at − 80 °C, otherwise | Genetic analyses, Virology |
| Blood or tissue culture | 5–10 g | Recipients with specific media, depend on local laboratory | Microbiology, Genetic analyses |
| Myocardium and other tissue samplesc | 1 × 1 × 1 mm | Karnovsky fixative, stored at 4° | Ultrastructural analysis (electron microscopy) |
Post-mortem specimens should be collected as soon as possible. The national and international quality management guidelines for standard autopsy sampling include several body fluids and tissues and describe appropriate technical methods. However, the extent of the sampling procedure will vary considerably from case to case, depending on autopsy results, circumstances of death, clinical data, requests, legal aspects, and availability. For most samples, disposable hard plastic or glass tubes are recommended
aor other location if peripheral blood not available
bliver, brain, lung, kidney, subcutaneous fat, and skeletal muscle
cin the suspicion of rare mitochondrial, storage, infiltrative diseases (tissues can be fixed in 2.5% glutaraldehyde only for short periods and must be processed promptly)
Cardiogenetic studies of family members: class of recommendations based on autopsy findings of the proband
| Finding autopsy | Age limit | Possible mutated genes | Class of recommendation for referral of first-degree family members for clinical/genetic counseling | Level of evidence [References] |
|---|---|---|---|---|
| Unknown/Uncertain cause of SCD | ≤ 40 | Mainly ion channels genes | I | C [ |
| Hypertrophic cardiomyopathy | No limit | Sarcomeric and other disease related genes | I | C [ |
| Arrhythmogenic cardiomyopathy | No limit | Desmosomal and other disease-related genes | I | C [ |
| Dilated cardiomyopathy | No limit | Sarcomeric, cytoskeleton and other disease-related genes | I | C [ |
| Premature atherosclerosis | Men < 40 Women< 50 | Familial hypercholesterolemia genes | IIa | C [ |
| Thoracic aortic aneurysm / dissection / rupture with medial degeneration | Unknown | Syndromic and non-syndromic aortic aneurysm-related genes | I | C [ |
| Spontaneous coronary artery dissection | No limit | Connective tissue disease-related genes | IIa | C [ |
| Pulmonary embolism | Unknown | Hereditary thrombophilia genes | IIba | C [ |
| SUDEP | Unknown | Overlap with ion channel-related genes | IIa | C [ |
Age limit refers to age of autopsy patient. SUDEP sudden unexpected death in epilepsy
Class of recommendation: I is recommended, IIa can be useful, IIb may be considered, III is not recommended
Level of evidence: A data derived from multiple randomized clinical trials or meta-analyses, B data derived from a single randomized clinical trial or large non-randomized studies. C consensus of opinion of the experts and/or small studies, retrospective studies, registries
amay be considered especially for patients without known risk factors for pulmonary embolism
Certainty of diagnosis of cardiovascular substrates of SCD at post-mortem
| Certain | Highly probable | Uncertain | |
|---|---|---|---|
| Coronary artery disease (native coronary arteries/stent/grafts/cardiac allograft) | Myocardial infarction, acute (any cause) | Chronic ischemic heart disease (ischemic scar, any cause) | Anomalous RCA origin from the left sinus with inter-arterial course |
| Acute coronary occlusion (atherothrombosis, arteritis, dissection or embolism, cardiac allograft vasculopathy) | Atherosclerotic plaque with coronary luminal stenosis > 75% | Wrong aortic sinus coronary artery anomalies without inter-arterial course | |
| Coronary ostia mechanical obstruction (aortic or valve prosthesis, tumor, vegetation) | Anomalous LCA origin from the right sinus with inter-arterial course | High take-off from the tubular portion | |
| Anomalous origin of the coronary artery from the pulmonary trunk | Anomalous LCx origin from the right sinus or coronary artery | ||
| Anomalous LAD origin with course anterior to the pulmonary artery | |||
| Coronary ostia plication | |||
| Intra-myocardial course of LAD (myocardial bridge) | |||
| Small vessel disease | |||
| Myocardial diseases | Acute diffuse myocarditis (any morphological type) | Hypertrophic CM | Focal myocarditis |
| Arrhythmogenic CM | Idiopathic LV hypertrophy | ||
| Dilated CM | |||
| Idiopathic fibrosis (non-ischemic LV scar) | Hypertensive heart disease | ||
| Multifocal myocarditis | Hypertrabeculation (non-compacted) myocardium | ||
| Sarcoidosis | |||
| Storage diseases | |||
| Amyloidosis | |||
| Native /prosthetic valves diseases | Mitral valve papillary muscle or chordae tendineae rupture with mitral valve incompetence and pulmonary edema | Calcific aortic valve stenosis with LV hypertrophy and fibrosis | Moderate aortic valve sclerosis without LV hypertrophy/ mitral annular calcification |
| Thrombotic block or endocarditis vegetations on valve prosthesis | Myxoid degeneration of the mitral valve (prolapse) with atrial dilatation or LV myocardial fibrosis and intact chordae | Dystrophic calcification of the membranous septum (+/− mitral annulus/aortic valve) | |
| Laceration/Dehiscence/Leaflet escape of valve prosthesis with acute valve incompetence | Aortic insufficiency (dilated aortic annulus) | ||
| Myxoid degeneration of the mitral valve (prolapse) without atrial dilatation or LV fibrosis and intact chordae | |||
| Conduction system diseases | AV node cystic tumor | Hemorrhage of the sub-aortic septum | |
| Purkinje cell hamartoma | Fibrosis of RBB and LBB (Lenègre disease) | ||
| Sarcoidosis of the AV conduction system | |||
| Surgical stiches, perimembranous | |||
| Congenital heart diseases | BAV and/or Isthmic coarctation with aortic dissection | Tetralogy of Fallot, surgical repair +/−pulmonary valve incompetence and RV dilatation | CHD with septal defect, no obstructive pulmonary vascular disease, repaired or unrepaired |
| Congenital aortic stenosis (supra-, sub- or valvular) or isthmic coarctation with LV hypertrophy and fibrosis | Any other unrepaired CHD | ||
| CHD with septal defects, repaired or unrepaired, and obstructive pulmonary vascular disease (Eisenmenger syndrome) | |||
| CHD with perimembranous VSD, postero-inferior rim stich | |||
| Corrected TGA (unrepaired) | |||
| Ebstein anomaly | |||
| Atrio-ventricular anomalous pathway (Kent fascicle) | |||
| TGA, atrial or arterial switch operation | |||
| CHD with RV-pulmonary artery conduit repair | |||
| CHD with univentricular or one and half repair | |||
| Ross operation | |||
| Others | Massive pulmonary embolism | Intramural ventricular/septal tumor | Atrial septum lipoma |
| Myxoma or other tumor/thrombus obstructing a valve orifice | Congenital partial absence of pericardium |
AV atrio-ventricular, BAV bicuspid aortic valve, CHD congenital heart disease, CM cardiomyopathy LAD left anterior descending, LBB left bundle branch, LCA left coronary artery, LCx left circumflex, LV left ventricle, RBB right bundle branch, RCA right coronary artery, RV right ventricle, TGA transposition of the great arteries, VSD ventricular septal defect
The gray zone between normal and/or secondary changes and pathologic changes of the myocardium
| Changes in the range of normality or secondary changes | Pathologic changes | Comments |
|---|---|---|
| Fatty infiltration of the right ventricular wall | Arrhythmogenic cardiomyopathy | Massive fatty infiltration of the right ventricle, without any evidence of replacement-type fibrosis and myocyte degeneration, should not be considered a diagnostic finding of arrhythmogenic cardiomyopathy, especially in obese, elderly people and people with alcohol abuse |
| Exercise-induced left ventricular hypertrophy (athlete’s heart) | Hypertrophic cardiomyopathy | An enlarged left ventricular cavity with increased wall thicknesses up to 13–14 mm is present in more than one third of highly trained athletes. Detailed histology essential |
| Focal myocardial disarray without hypertrophy | Hypertrophic cardiomyopathy without hypertrophy | Macroscopic changes are not always present in hypertrophic cardiomyopathy. Isolated myocardial disarray confined to the antero-septal and postero-septal junctions should be considered physiologic. For a confident diagnosis, additional findings, such as interstitial and/or replacement fibrosis and abnormal intramyocardial blood vessels should be searched for |
| Scattered inflammatory foci with or without small foci of fibrosis | Focal myocarditis | In the absence of myocyte necrosis, small foci of inflammatory cells (even after immunohistochemistry), are not sufficient evidence of myocarditis. Scattered small foci of fibrosis are also insignificant. |
| Circumferential, subendocardial myocardial ischemia+/− hemorrhage after resuscitative maneuvers | Regional or circumferential, sub-endocardial myocardial ischemia without resuscitative maneuvers | Ischemic changes of the myocardium, particularly when sub-endocardial and diffuse require exclusion of prolonged resuscitative maneuvers |